Obesity is a chronic metabolic disease affecting adults and children worldwide. It has
become one of the leading causes of death, as obesity is known to be the main risk factor for …

Trace amine-associated receptor 1 (TAAR1) has emerged as a promising therapeutic target
for neuropsychiatric disorders due to its ability to modulate monoaminergic and …

Aim Up to 60% of depressed patients do not obtain sufficient relief from a course of
antidepressant therapy, and these treatment-resistant major depressive disorder (TRD) …

Schizophrenia is a chronic, severe and highly complex mental illness. Current treatments
manage the positive symptoms, yet have minimal effects on the negative and cognitive …

Obesity, a new pandemic, is associated with an increased risk of death, morbidity, and
accelerated aging. The multiple therapeutic modalities used to promote weight loss are …

BACKGROUND: Approximately 25% of patients admitted to a hospital as a result of
depression are actually suffering from psychotic depression. Psychotic symptoms can be …

This review evaluates the impact of partial compliance on treatment outcomes in
schizophrenia and discusses strategies that may be implemented to enhance compliance …

Objective: To characterize a model of atypical antipsychotic drug‐induced obesity and
evaluate its mechanism. Research Methods and Procedures: Chronically, olanzapine or …

Ever since its pharmacologic discovery in 1983, 1 the histamine H3 receptor has provided a
tantalizing target for drug research, 25 years later still to be validated by an approved and …

The second generation antipsychotics clozapine and olanzapine are known to cause weight
gain. However, only clozapine is associated with drug-induced fever. Cytokines have been …